Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients

被引：0

作者：

Huang, Chin-Chou ^{[1
,2
,3
,4
,5
]}

Charng, Min-Ji ^{[2
,3
]}

机构：

[1] Taipei Vet Gen Hosp, Dept Med Educ, 201,Sec 2,Shih Pai Rd, Taipei 11217, Taiwan

[2] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, 201,Sec 2,Shih Pai Rd, Taipei 11217, Taiwan

[3] Natl Yang Ming Univ, Fac Med, Sch Med, Taipei, Taiwan

[4] Natl Yang Ming Univ, Cardiovasc Res Ctr, Taipei, Taiwan

[5] Natl Yang Ming Univ, Inst Pharmacol, Taipei, Taiwan

来源：

THERAPEUTICS AND CLINICAL RISK MANAGEMENT | 2019年 / 15卷

关键词：

Chinese; evolocumab; homozygous familial hypercholesterolemia; low-density lipoprotein; proprotein convertase subtilisin/kexin type 9; AMG; 145; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; PCSK9; INHIBITION;

D O I：

10.2147/TCRM.S193971

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Evolocumab, which can lower low-density lipoprotein (LDL) cholesterol levels by approximately 60% and prevent cardiovascular events in patients with cardiovascular disease, is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Some studies have investigated its efficacy and safety in the treatment of the homozygous form of familial hypercholesterolemia (HoFH), and others have focused on its efficacy and safety in Asians with high cardiovascular risk. Although no direct evolocumab clinical trials have been conducted in Chinese HoFH patients, its efficacy and safety in the Chinese population should be similar to those in other ethnic groups.

引用

页码：1209 / 1216

页数：8

共 50 条

[1] Evolocumab in patients with homozygous familial hypercholesterolemia in India
Bansal, Sandeep
Ruzza, Andrea
Sawhney, Jps
Kulkarni, Govind
Iyengar, Shammana
Mehta, Vimal
Hamer, Andrew
Wu, You
Raal, Frederick J.
JOURNAL OF CLINICAL LIPIDOLOGY, 2021, 15 (06) : 814 - 821
[2] Use of evolocumab in a patient with homozygous familial hypercholesterolemia
Negri, E. A.
Trenti, C.
Fasano, T.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 132 - 132
[3] Evolocumab for the treatment of homozygous familial hypercholesterolaemia
Blom, Dirk Jacobus
Marais, A. David
EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (07): : 789 - 798
[4] TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
SHARMA, SK
KAUSHAL, R
CHATTOPADHYAY, TK
BRITISH MEDICAL JOURNAL, 1985, 291 (6509): : 1644 - 1644
[5] Treatment of homozygous familial hypercholesterolemia
France, Michael
Schofield, Jonathan
Kwok, See
Soran, Handrean
CLINICAL LIPIDOLOGY, 2014, 9 (01) : 101 - 118
[6] Efficacy and Safety of Ongericimab in Chinese Patients With Homozygous Familial Hypercholesterolemia
Lin, Jie
Chen, Jiyan
Zhang, Ruiyan
Wang, Jingfeng
Bai, Xuelian
Yan, Hui
Yu, Jianjun
Yao, Sheng
Feng, Hui
Lin, Jie
CIRCULATION, 2022, 146
[7] LONG-TERM PLASMAPHERESIS IN THE TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN 2 CHINESE PATIENTS
WANG, C
WONG, KL
CHENG, CH
CHAN, TK
LIU, WT
LIN, HJ
TRANSFUSION SCIENCE, 1991, 12 (03): : 189 - 192
[8] Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
Raal, Frederick J.
Hegele, Robert A.
Ruzza, Andrea
Lopez, J. Antonio G.
Bhatia, Ajay K.
Wu, Johnny
Wang, Huei
Gaudet, Daniel
Wiegman, Albert
Wang, Jian
Santos, Raul D.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2024, 44 (05) : 1156 - 1164
[9] EVOLOCUMAB TREATMENT IN PAEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: DATA FROM THREE POOLED OPEN-LABEL STUDIES
Raal, F.
Ruzza, A.
Opez, J. A. L.
Bhatia, A.
Wu, J.
Wang, H.
Gaudet, D.
Wiegman, A.
Hegele, R.
Santos, R.
ATHEROSCLEROSIS, 2023, 379
[10] Clinical signs of homozygous familial hypercholesterolemia
Malyshev, PP
Shaklunova, OA
Kukharchuk, VV
KARDIOLOGIYA, 2002, 42 (08) : 30 - 33

← 1 2 3 4 5 →